NASDAQ:RVPH

Reviva Pharmaceuticals Q3 2025 Earnings Results & Report

Reviva Pharmaceuticals logo
$0.34 +0.05 (+17.96%)
As of 11/20/2026 03:57 PM Eastern

Reviva Pharmaceuticals beat analyst earnings expectations in its Q3 2025 results, released November 13, 2025. The company reported EPS of -$1.20 versus the -$2.20 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
7:00 AM ET

Reviva Pharmaceuticals EPS Results

Actual EPS
-$1.20
Consensus EPS
-$2.20
Beat/Miss
Beat by +$1.00
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Reviva Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Reviva Pharmaceuticals Q3 2025 Earnings FAQ

Reviva Pharmaceuticals (NASDAQ:RVPH) reported earnings of -$1.20 per share for Q3 2025, beating the consensus estimate of -$2.20. The report was announced on Thursday, November 13, 2025.

Reviva Pharmaceuticals Earnings Headlines

RVPH: FDA Feedback on New Formulation Imminent
Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
See More Reviva Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Reviva Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your email.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals (NASDAQ:RVPH) is a clinical-stage biopharmaceutical company focused on developing treatments for disorders involving the central nervous system, respiratory system and inflammation. The company is headquartered in Cupertino, California, and was founded in 2006.

Its lead drug candidate, brilaroxazine (also known as RP5063), is an investigational compound being developed for schizophrenia and other neuropsychiatric conditions. Reviva has also described potential applications for the candidate in respiratory and other disorders. Brilaroxazine is not an approved or marketed medicine.

Reviva’s work centers on research and clinical development of its drug candidates; the company does not currently offer commercial pharmaceutical products.

View Reviva Pharmaceuticals Profile